Ourotech competitors

Ourotech's competitors include Aptevo Therapeutics, Geron Corporation, Immune Design and Aeglea Biotherapeutics
Add company...
Ourotech
Ourotech is changing the way cancer drugs are tested for the most innovative treatments.
Aptevo Therapeutics
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.
Geron Corporation
Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Immune Design
Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.
Aeglea Biotherapeutics
Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer.
Founding Date
Founding Date
2015
Founding Date
2016
Founding Date
1990
Founding Date
2008
Founding Date
2013
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Waterloo, CA HQ
Locations
Seattle, US HQ
Locations
Menlo Park, US HQ
Canton, US
Locations
Seattle, US HQ
South San Francisco, US
Locations
Austin, US HQ
Employees
Employees
4
Employees
118
Employees
15
Employees
50
Employees
4518% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
127.6 m
Valuation ($)
727.1 m
Valuation ($)
151.7 m
Valuation ($)
202.8 m

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$14.7m (FY, 2017)
Revenue (est.)
$1.1m (FY, 2017)
Revenue (est.)
$7.2m (FY, 2017)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
$5m (FY, 2017)
Cost of goods
N/A
Cost of goods
$84k (FY, 2017)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$9.6m (FY, 2017)
Gross profit
N/A
Gross profit
$7.1m (FY, 2017)
Gross profit
N/A
Net income
Net income
N/A
Net income
$7m (FY, 2017)
Net income
($27.9m) (FY, 2017)
Net income
($51.9m) (FY, 2017)
Net income
($27.2m) (FY, 2017)

Operating

Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
2 (FY, 2016)
For sources of this data, please see the company profileDownload Excel

View company profiles

Aptevo Therapeutics
HQ
Seattle, US
Employees
118

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.

View company
Geron Corporation
HQ
Menlo Park, US
Employees
15

Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

View company
Immune Design
HQ
Seattle, US
Employees
50

Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.

View company
Aeglea Biotherapeutics
HQ
Austin, US
Employees
45↑ 18% increase

Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer.

View company